We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ALGS market cap is 143.87M. The company's latest EPS is USD -24.4375 and P/E is -1.66.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 3.24M | 2.68M | 986k | 1.06M | 1.27M |
| Operating Income | -18.21M | -26M | -22.05M | -26.41M | -20.13M |
| Net Income | -18.11M | -27.89M | -34.86M | 5.06M | -19.26M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 4.36M | 13.91M | 15.53M |
| Operating Income | -54.04M | -97.83M | -128.32M | -97.58M | -88.13M |
| Net Income | -52.26M | -108.54M | -128.33M | -96.05M | -87.68M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 85.85M | 151.53M | 127.9M | 108.81M | 88.43M |
| Total Liabilities | 31.03M | 59.45M | 68.11M | 41.58M | 38.33M |
| Total Equity | 54.82M | 92.08M | 59.8M | 67.23M | 50.1M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 146.52M | 265.3M | 235.37M | 146.69M | 151.53M |
| Total Liabilities | 29.33M | 45.26M | 50.64M | 42.79M | 59.45M |
| Total Equity | -64.89M | 220.04M | 184.73M | 103.9M | 92.08M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -56.34M | -79M | -22.75M | -42.24M | -62.34M |
| Investing | 44.99M | 44.98M | -88.64M | -48.65M | -38.25M |
| Financing | 392k | 88.33M | -19k | 262k | 258k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -46.77M | -74.26M | -115.66M | -79.39M | -79M |
| Investing | 6.79M | 32.76M | 3.02M | -26.29M | 44.98M |
| Financing | 85.53M | 192.35M | 78.68M | 164k | 88.33M |
| Market Cap | 143.87M |
| Price to Earnings Ratio | -1.66 |
| Price to Sales Ratio | 9.35 |
| Price to Cash Ratio | 1.07 |
| Price to Book Ratio | 1.58 |
| Dividend Yield | - |
| Shares Outstanding | 3.59M |
| Average Volume (1 week) | 484.5k |
| Average Volume (1 Month) | 444.94k |
| 52 Week Change | 141.38% |
| 52 Week High | 44.39 |
| 52 Week Low | 6.76 |
| Spread (Intraday) | 1.91 (4.66%) |
| Company Name | Aligos Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.aligos.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
